Our Healthcare Services

We produce a diverse array of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. Dei Biopharma Ltd makes the vital drugs including all types of vaccines on top of the mRNA vaccines, and essential drugs including the Filgrastim, Eryth- ropoietin, and Trastuzumab, among several others.
analytics

Inactivated Vaccines

Used to protect against:- Chickenpox (Varicella), Diphtheria, Flu (Influenza), Hepatitis A,  and Rabies.

design_services

Live-attenuated vaccines

Used to protect against:- Measles, mumps, rubella (MMR combined vaccine), Rotavirus, Smallpox, Chickenpox and Yellow fever.

api

Messenger RNA (mRNA)

These are the Vaccines that are used to protect against:- COVID-19 and other severe acute respiratory syndrome coronavirus 2

Conjugate vaccines

Subunit, recombinant, polysaccharide, and conjugate vaccines are used to protect against:- Hib (Haemophilus influenzae type b) disease- Hepatitis B- HPV (Hu- man papillomavirus)- Whooping cough (part of the DTaP com- bined vaccine)- Pneumococcal disease- Meningococcal disease- Shingles).

Toxoid vaccines

These Vaccines are used to pro- tect against DiphtheriaTetanus.

Viral vector vaccines

These Vaccines are used to protect against:COVID-19.

Some of the experts from the World Health Organisation during inspection of the Dei BioPharma biological drugs and vaccines manufacturing facility in Mattuga, Wakiso district.

We Provide Inspiring Ideas

Dei Biopharma has an offtake agreement with the Gov- ernment of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biop- harma has established the following facilities in the project;

  1. The Generics section
  2. The Nutraceuticals section
  3. The Oncology/cancer drugs
  4. Penicillin section
  5. The Cephalosporins section
  6. Non Beta lactum section
  7. The Injectable facilities
  8. The WFI facility
  9. The Parentals
  10. The Ophthalmolic facility

We Provide Inspiring Ideas

Dei Biopharma has an offtake agreement with the Gov- ernment of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biopharma has established the following facilities in the project;

  1. The Generics section
  2. The Nutraceuticals section
  3. The Oncology/cancer drugs
  4. Penicillin section
  5. The Cephalosporins section
  6. Non Beta lactum section
  7. The Injectable facilities
  8. The WFI facility
  9. The Parentals
  10. The Ophthalmolic facility

Dei Biopharma Ltd has also set up the iconic YKTM GLP Biotech Laboratories that includes the following components ;-

Cancer research, QA/QC, drug discovery, Gene therapy, cell therapy, mRNA therapeutics, vaccines, biosimilars and Biologics.

The facility will, importantly, have biological facilities to manufacture biological drugs, biosimilars, cytokines, therapeutic protein, peptides and monoclonal antibodies

The above is what makes this facility so unique and is the reason, it will cost us more than $1 billion.

The Moderna facility in Kenya making only mRNA will cost $500 million, and in comparison, considering that this is just a small component of what Dei Biopharma Ltd is putting up in Uganda, is much cheaper.

The Dei Biopharma mRNA facility has capacity to produce more than one billion doses of mRNA vaccines per year and will have a turnover of USD 10 billion annually in the 10th year.

Dei BioPharma Ltd.